Dilution of Verapamil During Intraarterial Administration

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous coronary angiography via TRA will be included. Patients who are non-English speaking, pregnant, or intubated will be excluded. Patients will be randomized to one of the two following groups:

1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline

2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL)

The investigators will document the patient's level of discomfort on the Visual Analogue Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The investigators will also document the presence of radial artery spasms.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Treatments: Calcium Channel Blockers; Nicardipine; Verapamil

Criteria

Inclusion Criteria

• English Speaking patients who are age 18 or older

• Patient must be able to provide own consent and communicate with staff

• Patient's undergoing transradial access (TRA) for the left heart catheterization (LHC)

Exclusion Criteria

• Intubated or sedated patients

• Agitated patients requiring moderate sedation prior to TRA

• Patient's undergoing femoral access for the LHC

• Non-English speaking patients

• Contraindications to Verapamil or Nicardipine: including allergies to these medications, hypotension (mean arterial pressure <65), Bradycardia (heart rate<40)

• Emergent cardiac catheterization

• Inability to obtain radial artery access

• Conversion to radial artery access from another access site